JW (Cayman) Therapeutics Co Ltd
HKEX:2126
JW (Cayman) Therapeutics Co Ltd
Cash from Operating Activities
JW (Cayman) Therapeutics Co Ltd
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
|
Cash from Operating Activities
-¥536.7m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Cash from Operating Activities
-¥7.8B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Cash from Operating Activities
-¥1.7B
|
CAGR 3-Years
-78%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash from Operating Activities
¥1.5B
|
CAGR 3-Years
49%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cash from Operating Activities
¥3.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
106%
|
CAGR 10-Years
47%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cash from Operating Activities
¥1.2B
|
CAGR 3-Years
57%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
See Also
What is JW (Cayman) Therapeutics Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
-536.7m
CNY
Based on the financial report for Dec 31, 2023, JW (Cayman) Therapeutics Co Ltd's Cash from Operating Activities amounts to -536.7m CNY.
What is JW (Cayman) Therapeutics Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-38%
Over the last year, the Cash from Operating Activities growth was 0%. The average annual Cash from Operating Activities growth rates for JW (Cayman) Therapeutics Co Ltd have been -27% over the past three years , -38% over the past five years .